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Context: Low bone mineral density (BMD) is the most important risk factor for fragility
fracture. Body weight is a simple screening predictor of difference in BMD between
individuals. However, it is not clear which component of body weight, lean (LM), or fat
mass (FM), is associated with BMD. People with the genetic disorder of Prader-Willi
syndrome (PWS) uniquely have a reduced LM despite increased FM.
Objective: We sought to define the individual impact of LM and FM on BMD by
investigating subjects with and without PWS.
Design, Setting and Participants: This cross-sectional study was conducted at the
Clinical Research Facility of the Garvan Institute of Medical Research, with PWS and
control participants recruited from a specialized PWS clinic and from the general public by
advertisement, respectively. The study involved 11 adults with PWS, who were age- and
sex-matched with 12 obese individuals (Obese group) and 10 lean individuals (Lean
group).
Main Outcome Measures: Whole body BMD was measured by dual-energy X-ray
absorptiometry. Total body FM and LM were derived from the whole body scan.
Differences in BMD between groups were assessed by the analysis of covariance model,
taking into account the effects of LM and FM.
Results: The PWS group had significantly shorter height than the lean and obese
groups. As expected, there was no significant difference in FM between the Obese
and PWS group, and no significant difference in LM between the Lean and PWS group.
However, obese individuals had greater LM than lean individuals. BMD in lean individuals
was significantly lower than in PWS individuals (1.13 g/cm2 vs. 1.21 g/cm2, p < 0.05)
and obese individuals (1.13 g/cm2 vs. 1.25 g/cm2, p < 0.05). After adjusting for both
LM and FM, there was no significant difference in BMD between groups, and the only
significant predictor of BMD was LM.
Conclusions: These data from the human genetic model Prader-Willi syndrome suggest
that LM is a stronger determinant of BMD than fat mass.
Keywords: Prader-Willi Syndrome, bone mineral density (BMD), fat mass, lean mass, body composition, human
model, genetic model
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INTRODUCTION
Low bone mineral density (BMD) is the most robust risk factor
for fragility fractures. Each standard deviation lower in BMD is
typically associated with a ∼2-fold increase in fracture risk (1).
The variation in BMD between individuals is largely determined
by body size, but age, gender, and body composition modify
the effect of increased body size (2). While mechanical factors
associated with the increased weight-bearing requirement of
greater body mass play a part, bone turnover is influenced by the
amount of lean mass (LM) and fat mass (FM), the metabolically
active components of total body mass. With age however, higher
BMI, or body weight is associated with osteoporosis and fracture
(3).
A number of cross-sectional population-based studies have
investigated the relationships between the components of body
mass and BMD. Some studies identified LM as a strong
determinant of BMD, while some found that FM alone was
a determinant. Others showed that both LM and FM were
associated with BMD [collated in (4)]. A recent systematic
review and meta-analysis of 2,587 overweight and obese
subjects found a positive correlation of total adiposity with
BMD but a negative one with relative adiposity (5). Such
investigations were recently the subject of a meta-analysis,
which aimed at clarifying these relationships across gender, age,
and ethnicity. This meta-analysis of 20,226 individuals in 44
studies found that, while LM and FM were both associated
with BMD in men and women combined, LM was more
strongly predictive, with ∼21% of whole body BMD difference
attributable to variation in LM compared to 8% for FM
(4).
One of the greatest difficulties in teasing apart the individual
associations of BMD with FM and LM is that the two factors are
statistically correlated. Thus, it is difficult to determine which is
more closely related to BMD and this calls for a novel approach.
PWS, a genomic imprinting disorder, is one of the most
common genetic types of obesity, caused by a loss of expression
of a critical genomic region on the paternal allele of chromosome
15q11–q13 and is characterized by hypotonia and failure to thrive
in infancy followed by hyperphagia starting in childhood, with
onset at ∼2–6 years of age. Prader-Willi syndrome (PWS) is the
ideal humanmodel to investigate the relative contributions of FM
and LM to BMD, as this syndrome is characterized by increased
adiposity accompanied by low muscular mass, in contrast to
other forms of obesity (6). Skeletal disorders are a common
feature of PWS. Between 60% and 90% of individuals with PWS
have osteoporosis with a high fracture rate, while up to 80%
experience scoliosis (7–10). Reduced BMD and bone mineral
content (BMC) compared to obese controls have been reported
in adults with PWS (11–14), with low levels of growth hormone
(GH) and/or sex hormones, and reduced physical activity, as
contributory causes.
In this study, we sought to define the individual impact of LM
and FMon BMDby investigating subjects with andwithout PWS,
a unique human model of genetic obesity with a high FM but low
LM, compared to weight matched obese subjects with higher FM
and LM as lean control subjects.
MATERIALS AND METHODS
Subjects
The cross-sectional study compared three groups of individuals:
a PWS cohort, a weight-matched obese group, and a lean
group. Individuals with a cytogenetically confirmed diagnosis of
PWS (n = 11) were recruited from the Prader-Willi Syndrome
Clinic at the Royal Prince Alfred Hospital (Camperdown, NSW,
Australia). The obese group (n = 12) and lean group (n = 10)
were recruited by public advertisement. They were matched for
gender and ethnicity; one member of each group was Asian, with
the rest being Caucasian. Because of the heterogeneity of the PWS
cohort, matching was conducted by recruiting control groups
with similar gender, age, ethnicity, BMI and presence of diabetes,
rather than by case to case matching.
Three PWS group members had type 2 diabetes (T2D; treated
with metformin alone, metformin and gliclazide, and metformin
and Mixtard 30/70; mean HbA1c 7.3%). One woman with
PWS was treated with sex hormone replacement therapy and
5 men with PWS received low dose testosterone. None of the
participants with PWS had received growth hormone treatment
in the past, as at the time of the study, growth hormone was not
available under the public health care system. Two individuals in
the obese control group had T2D (treated with metformin and
gliclazide, and metformin, sitagliptin and rosiglitazone; mean
HbA1c 7.6%).
The study’s protocol and procedures were approved by the
Human Ethics Committee of St. Vincent’s Hospital and Royal
Prince Alfred Hospital. All participants (or in the case of the
PWS participants, their parents/guardians) have given written
informed consent.
Data Collection
Height was measured with a wall-mounted stadiometer and body
weight after voiding was measured by an electronic scale. BMI
was calculated as weight in kg divided by height inmeters squared
(kg/m2). Information about daily activity level and ethnicity was
collected via a standardized questionnaire administered by a
research nurse.







Age (yr) 28.8 (3.6) 31.9 (8.7) 27.6 (8.1)
Gender (m/f) 5/5 7/5 7/4
Height (cm) 168.7 (9.3) 167.8 (7.2) 154.7 (12.0)
Weight (kg) 60.9 (7.1) 95.9 (7.7) 88.9 (21.6)
BMI (kg/m2) 21.4 (0.4) 34.2 (1.2)a 37.4 (2.7)b
Fat mass (kg) 14.8 (5.5) 40.5 (11.7)a 43.3 (15.4)b
Percent body fat (%) 19.0 (2.6) 43.1 (10.3)a 49.0 (8.4)b
Lean mass (kg) 44.4 (9.0) 52.9 (9.0)a 43.4 (8.4)
Bone mineral density (g/cm2) 1.13 (0.06) 1.25 (0.07)a 1.21 (0.07)
Data presented as mean (standard error). Significant differences (p < 0.05): a, Obese vs.
Lean; b, PWS vs. Lean.
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FIGURE 1 | Distribution of fat mass, lean mass, and bone mineral density from individuals within the Lean, Obese and PWS group. *p < 0.05 between groups.
TABLE 2 | Predictors of bone mineral density: multiple linear regression analysis.
Variable Coefficient Standard error P-value
Group (Obese) 0.053 0.042 0.222
Group (PWS) 0.028 0.044 0.531
Fat mass 0.001 0.001 0.337
Lean mass 0.005 0.001 0.024
Height 0.002 0.002 0.356
Age −0.0003 0.002 0.837
Multiple linear regression model with age, height, lean mass and fat mass as predictors
of BMD. A p-value of <0.05 was considered significant.
All study participants underwent whole body dual-energy X-
ray absorptiometry scan (DXA) (Lunar DPX GE-Lunar, Lunar
Corp., Madison, WI). From the whole body scan, total lean mass
(kg), fat mass (kg), body fat (%) and BMD (g/cm2) were derived
as previously described (15).
Statistical Analysis
Analysis of covariance model (ANCOVA) was used to estimate
pairwise difference in BMD and body composition parameters
between groups. Multiple linear regression modeling was used
with age, height, LM, and FM as predictors of BMD (Table 2).
In order to control for experiment-wise error rate and false
positives, we used the Tukey’s range test (also known as
the “honest significance difference” test). All analyses were
performed with the R Statistical Environment system (R
Development Core Team, 2008).
RESULTS
As expected, there was no significant difference in FM between
PWS and Obese individuals, but FM of the Obese and PWS
groups was significantly higher than the Lean group (Table 1).
On the other hand, the Obese group had greater LM compared
with the Lean group, but there was no significant difference
between PWS and Lean or between PWS and Obese groups in
terms of LM (Figure 1).
Whole body BMD in Obese individuals was significantly
higher than Lean individuals, with mean difference being 0.12
g/cm2 (95% CI 0.05 to 0.19). Nevertheless, there was no
statistically significant difference in BMD between PWS and Lean
or between PWS and Obese groups (Table 1).
In the multiple linear regression model with age, height,
LM and FM as predictors, none of the differences in BMD
between groups were statistically significant (Table 2).
Among the predictors, only LM remained as a small
(coefficient 0.005 but significant determinant of BMD
p= 0.02).
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DISCUSSION
This study utilized a unique genetic disorder to dissect the
influences of components of body composition on BMD. Despite
close general similarity in body composition between PWS and
Obese, after correcting for the association between LM and FM
themselves, we found that LM was still an independent predictor
of BMD. These findings support those of Ho-Pham et al, who
found LM to be a stronger predictor of BMD than FM across
gender, age, and ethnicity (4).
The inter-relationships between muscle, fat and bone
are complex, with far-reaching implications for osteoporosis,
sarcopenia, geriatric frailty, and obesity. There is a great deal
of endocrine and immune cross-talk between the three organs,
mediated through circulating factors including, among others,
adiponectin, osteocalcin, interleukin-6, leptin, and fatty acids.
The relationship between muscle and bone is particularly
strong linked by genetic, developmental, and physiological
factors.
Population-based studies have shown BMD and LM to be
highly associated, with genetic factors responsible for more
than half of this correlation at some anatomical sites (16). In
investigating this heritability, bivariate linkage analysis studies
have identified shared genomic regions between LM and both
BMD and bone geometric parameters (17, 18), as well as
specific genes linked to both osteoporosis and sarcopenia
(19, 20).
The relationship between muscle (the major component of
LM) and bone may be a causative one: Harry et al found that
open tibial fractures in mice displayed faster and more complete
healing when directly covered with a flap of muscle than when
covered with fascio-cutaneous tissue (21). This effect is thought
to be mediated by muscle tissue—in close proximity to the
fracture—promoting revascularisation and secreting osteogenic
factors such as muscle-derived stem cells and growth factors (22–
26). Indeed, the apposition of muscle to fractures by soft tissue
reconstruction has been recommended to promote healing in
humans (24).
The strength of this study is the unique opportunity to
use a live human genetic model of obesity where LM and
FM are not associated with each other, as they usually are in
general obesity. The phenotype of all subjects has well been
characterized, showing that PWS have a similar LM to lean
controls, but together with a similar FM to obese controls.
These clean and well matched groups provide further insight
into the relationship of body composition and BMD, despite
the limitation of our relatively small sample size. Studying a
large cohort of subjects with the rare disease of PWS remains a
logistical challenge.
Given the commonly-seen short stature in people with PWS,
we attempted to recruit short obese and lean control subjects
to minimize the inter-group height discrepancy. Despite this,
there was still a small difference in height between PWS and
Obese (p = 0.006) and between PWS and Lean (p = 0.007).
However, due to the high prevalence of scoliosis in our PWS
cohort, their “true height” is likely to be greater than measured
height, bringing them closer to control subjects.
One limitation of the current study was the use of total body
DXA without individual scans at the femoral neck or lumbar
spine. While these sites are commonly used to assess fracture risk
rather than to interrogate general body composition associations
per se, this would be a useful future direction for further studies
in this area.
Another notable limitation of this study is that some other
factors than LM/FM which can affect BMD have not been
accounted for. PWS is recognized to present with a hypothalamic
dysfunction which is responsible for the hyperphagia, for growth-
hormone and thyroid-stimulating hormone deficiencies, central
adrenal insufficiency, and hypogonadism. It also leads to a low
drive to physical activity and hypotonia. Some of these factors
may act on BMD indirectly by lowering LM, but others might
impact BMD independently, and the impact of these is hard to
measure.
In conclusion, utilizing the unique human genetic model PWS
in which fat mass and lean mass are not positively correlated, we
found that, of the two, lean mass was more strongly associated
with BMD. This supports the findings of genetic linkage analyses
as well as studies investigating the direct and indirect effects
of muscle on bone. These findings have implications in the
treatment (and prevention) of osteoporosis, sarcopenia and
geriatric frailty (independent of high weight), in that therapies
designed to target either bone or muscle tissue (eg. myostatin
antagonism) may have pleiotropic beneficial effects on both.
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